The epidemiology of extrapyramidal reactions to metoclopramide was studied by examining reports in the Adverse Reactions Register of the Committee on the Safety of Medicines and comparing these with prescribing figures by general practitioners in the United Kingdom for metoclopramide (Maxolon). In the period 1967-82 there were an estimated 15-9 million prescriptions and 479 reports of extrapyramidal reactions (455 of dystonia-dyskinesia, 20 of parkinsonism, and four of tardive dyskinesia). When corrected for prescribing rates the relative risk of dystonia and dyskinesia was 1-8 in female compared with male patients (95% confidence interval 1 4-2 2). The overall reporting rate for dystonia and dyskinesia was 28-6/million prescriptions but was significantly more common in young adults (p <0 0001) and especially girls and women aged 12-19 (190 7 reports/ million prescriptions). By contrast parkinsonian reactions were significantly more common in the elderly (p <0-0001).
Introduction
Extrapyramidal reactions are well recognised adverse effects of drugs with dopamine receptor antagonist properties. With phenothiazine neuroleptic drugs the frequency of extrapyramidal reactions seems to correlate with their antipsychotic potency, and dystonic and dyskinetic symptoms occur most often in patients aged under 45 years. ' Since the introduction of meto- clopramide (a selective D2 dopamine antagonist) as an antiemetic drug in 1967 numerous reports have been published about an association between its administration and the occurrence of various extrapyramidal reactions,2 6 
PARKINSONISM
Twenty patients (15 female) were reported as developing parkinsonism in association with metoclopramide, and 15 were aged over 55 years. Only seven of the reactions developed within three days of starting treatment with metoclopramide, and seven occurred after more than 28 days of treatment (two of these after five years). All patients recovered after withdrawal of the drug, although in some cases this took several months. Nine patients were receiving other drugs (table III) , and the median dose was 30 (range 20-40) mg/24 hours.
The reporting rates per million prescriptions were 0-58 (male) and 0-56 (female) in patients under 65 years and 1-7 (male) and 4-2 (female) for those aged 65 and over. The difference in rates between the sexes was not significant (X2J = 0 80) but there was a significantly higher rate in the elderly (X2 138; p<0 0001)
Discussion
The occurrence of extrapyramidal reactions with metoclopramide is well recognised and most previously published case reports of acute dystonias or dyskinesias have been in female patients under 25 years of age.3 7 The incidence of acute dystonia-dyskinesia observed by the Boston Collaborative Drug Surveillance Program was one in 758 hospital inpatients of unrecorded age.8 In a survey from Sardinia all patients presenting at hospital with acute dystonia over nine months were aged 8-42, and in 36 of the 94 patients metoclopramide was the implicated drug. 4 This study shows that the yellow card reporting of adverse reactions to metoclopramide depends on both age and sex: acute dystonic-dyskinetic reactions are reported predominantly in younger female patients, and with many fewer reports of parkinsonian reactions predominantly for older patients. These differences in age and sex between reporting rates could come from bias due to a relative failure to report acute dystonicdyskinetic reactions in adults over the age of 40. This seems unlikely: firstly, reports of adverse reactions to drugs to the Committee on the Safety of Medicines generally tend to increase with age and, secondly, reports of parkinsonism associated with metoclopramide occur predominantly in older patients. The differences in age and sex cannot be attributed to differences in prescribing. The figures for prescriptions provided by Intercontinental Medical Statistics Limited are estimates (to the nearest thousand) based on a sample of general practitioners in the United Kingdom; they are the best estimates available. Although they exclude prescribing in hospitals, these comprise only 10% of all prescriptions for metoclopramide (Beecham Pharmaceuticals, personal communication). In performing the analysis of proportions of reported reactions we have treated these figures as if they were exact rather than approximate; unless there are gross errors in the magnitude of these estimates or differential errors for the various age or sex groups this should not affect our conclusions.
In the absence of any clear evidence of bias in reporting we conclude that there are real differences in age and sex in the incidence of acute dystonic-dyskinetic reactions with metoclopramide, and that girls and women aged [12] [13] [14] [15] [16] [17] [18] [19] are at special risk.
In this group of female patients the reporting rate of acute extrapyramidal reactions is roughly 1 in 5000: this figure is, however, likely to be a substantial underestimate of the true incidence in view of the known under-reporting (90-99%) of adverse reactions to drugs9 and the fact that the prescribing data, although excluding prescribing in hospitals, do not take account of repeated prescriptions. The mechanism for this apparent susceptibility is uncertain. Although many of the children were prescribed doses of metoclopramide above those recommended by manufacturers, relative overdosage, as discussed earlier, does not account for the differences in age and sex. Therapeutic overdosage in the 12-19 year age group may contribute to the high reporting rate, but exclusion of those patients who were prescribed a relative overdose from the analysis means that the sex difference in reporting becomes more pronounced in this age group (table V) . As we do not have details of prescribing dosages to the community as a whole assessment of the dose response relation in terms of adverse reactions is impossible. Plasma concentrations and clearances of metoclopramide, however, were similar in children suffering from acute extrapyramidal reactions to those not suffering.'0 Furthermore, prescribing a relative overdose does not account for the age related pattern of reports in the age groups over 20 years, and we therefore favour a pharmacodynamic explanation. This would be supported by the observation that the prolactin response to intravenous metoclopramide, which is due to the dopamine antagonist action of the drug, was substantially greater in 17-20 year old women than men." Moreover, an age related decline in density of D2 receptors has been shown to occur in the striatum of the rat"2 and in the caudate nucleus, putamen, and frontal cerebral cortex of man. '3 Only a fairly small proportion of patients were apparently receiving other drugs (table III) Although acute dystonic-dyskinetic reactions to metoclopramide are self limiting and rarely cause permanent damage, their morbidity is high and many patients reported to the Committee on the Safety of Medicines were admitted to hospital. In the light of present evidence it would seem wise to exercise care in the use of this drug in young people, and especially girls and young women.
Introduction
Despite continuing controversyl 2 it is widely believed that breast feeding partially protects against the development of allergic disease, including atopic eczema.3 This protective effect is not complete, however, as breast fed children sometimes
